应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
IONS Ionis Pharmaceuticals, Inc
交易中 08-16 10:33:04 EDT
46.65
-0.01
-0.03%
最高
46.88
最低
46.22
成交量
6.17万
今开
46.88
昨收
46.67
日振幅
1.41%
总市值
68.21亿
流通市值
67.62亿
总股本
1.46亿
成交额
287.60万
换手率
0.04%
流通股本
1.45亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Ionis Pharmaceuticals, Inc.2024财年第二财季实现净利润-66.27百万美元,同比增加22.30%
自选股智能写手 · 08-10
Ionis Pharmaceuticals, Inc.2024财年第二财季实现净利润-66.27百万美元,同比增加22.30%
Ionis Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.05%报46.65美元
自选股智能写手 · 08-05
Ionis Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.05%报46.65美元
高盛:维持Ionis Pharmaceuticals(IONS.US)评级,由卖出调整至卖出评级, 目标价由33.00美元调整至37.
智通财经 · 08-03
高盛:维持Ionis Pharmaceuticals(IONS.US)评级,由卖出调整至卖出评级, 目标价由33.00美元调整至37.
Ionis Pharmaceuticals, Inc.盘中异动 早盘大幅下跌5.03%报48.74美元
自选股智能写手 · 08-02
Ionis Pharmaceuticals, Inc.盘中异动 早盘大幅下跌5.03%报48.74美元
加拿大蒙特利尔银行:下调Ionis Pharmaceuticals(IONS.US)评级,由优于大市调整至大市一致评级, 目标价由67.
智通财经 · 08-02
加拿大蒙特利尔银行:下调Ionis Pharmaceuticals(IONS.US)评级,由优于大市调整至大市一致评级, 目标价由67.
Ionis Pharmaceuticals Inc 报告截至 6 月的季度业绩 - 收益摘要
Reuters · 08-01
Ionis Pharmaceuticals Inc 报告截至 6 月的季度业绩 - 收益摘要
Ionis Pharmaceuticals Inc 预计每股亏损 92 美分 - 财报前瞻
Reuters · 07-31
Ionis Pharmaceuticals Inc 预计每股亏损 92 美分 - 财报前瞻
BUZZ--美国股票走势-FTAI Aviation、Check Point、Sage Therapeutics
Reuters · 07-25
BUZZ--美国股票走势-FTAI Aviation、Check Point、Sage Therapeutics
BUZZ-利瑞克合伙公司(Leerink Partners)评级提升 Ionis 制药公司股价
Reuters · 07-24
BUZZ-利瑞克合伙公司(Leerink Partners)评级提升 Ionis 制药公司股价
TD Cowen:维持Ionis Pharmaceuticals(IONS.US)评级,由买入调整至买入评级, 目标价由54.
智通财经 · 07-24
TD Cowen:维持Ionis Pharmaceuticals(IONS.US)评级,由买入调整至买入评级, 目标价由54.
美国研究综述-高露洁-棕榄公司、麦凯森公司、微软公司
Reuters · 07-23
美国研究综述-高露洁-棕榄公司、麦凯森公司、微软公司
BUZZ-Ionis制药公司因神经紊乱药物研究数据而上涨
Reuters · 07-23
BUZZ-Ionis制药公司因神经紊乱药物研究数据而上涨
Ionis Pharmaceuticals, Inc.盘中异动 股价大涨5.33%报50.37美元
自选股智能写手 · 07-22
Ionis Pharmaceuticals, Inc.盘中异动 股价大涨5.33%报50.37美元
B of A Securities:维持Ionis Pharmaceuticals(IONS.US)评级,由买入调整至买入评级, 目标价由64.
智通财经 · 07-17
B of A Securities:维持Ionis Pharmaceuticals(IONS.US)评级,由买入调整至买入评级, 目标价由64.
Ionis Pharmaceuticals, Inc.盘中异动 股价大涨5.07%报49.98美元
自选股智能写手 · 07-16
Ionis Pharmaceuticals, Inc.盘中异动 股价大涨5.07%报49.98美元
Ionis Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.01%报46.92美元
自选股智能写手 · 06-25
Ionis Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.01%报46.92美元
美国研究综述-Alimera Sciences、Comtech Telecommunications、礼来公司
Reuters · 06-25
美国研究综述-Alimera Sciences、Comtech Telecommunications、礼来公司
Ionis Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.19%报44.00美元
自选股智能写手 · 06-25
Ionis Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.19%报44.00美元
BUZZ-Alnylam 因心脏病药物在关键研究中获得成功而跃升
Reuters · 06-25
BUZZ-Alnylam 因心脏病药物在关键研究中获得成功而跃升
伯恩斯坦研究公司:上调Ionis Pharmaceuticals(IONS.US)评级,由低于大市调整至大市一致评级。
智通财经 · 06-14
伯恩斯坦研究公司:上调Ionis Pharmaceuticals(IONS.US)评级,由低于大市调整至大市一致评级。
加载更多
公司概况
公司名称:
Ionis Pharmaceuticals, Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
伊奥尼斯制药公司在反义药物发明和开发上处于行业领先地位,利用新药研发平台,公司研发了大量的一流药品。反义技术在基因学和药物之间打开了一条通道。凭着公司高效多产的药物研发平台,公司可以用反义药物拓展自身及其合作伙伴的药物种类,满足大量的药物需求。公司的策略是做公司最擅长的事--寻找独特的反义药物并开发这些药物,使其成为关键的临床值转折点。公司发明并进行新药早期研究,然后将药物授权给合作伙伴。公司通过把药物交给领先的制药公司进行后期开发来实现药物的最大价值,如Biogen Idec公司、百时美施贵宝公司、 健赞公司、赛诺菲公司、葛兰素史克公司和礼来制药公司。 该公司的旗舰产品 KYNAMRO,正朝着市场上家族性高胆固醇血症患者迈进。 该公司于1989年在美国加州成立。
发行价格:
--
{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":46.65,"timestamp":1723818767038,"preClose":46.665,"halted":0,"volume":61702,"delay":0,"floatShares":144952447,"shares":146211091,"eps":-2.529241,"marketStatus":"交易中","marketStatusCode":2,"change":-0.015,"latestTime":"08-16 10:33:04 EDT","open":46.88,"high":46.88,"low":46.22,"amount":2876025.117676,"amplitude":0.014143,"askPrice":46.68,"askSize":156,"bidPrice":46.62,"bidSize":288,"shortable":3,"etf":0,"ttmEps":-2.529241,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1723838400000},"adr":0,"adjPreClose":46.665,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":46.665,"preClose":46.665,"latestTime":"19:05 EDT","volume":13358,"amount":623366.85,"timestamp":1723763131195},"volumeRatio":0.442317,"impliedVol":0.311,"impliedVolPercentile":0.0595},"requestUrl":"/m/hq/s/IONS","defaultTab":"news","newsList":[{"id":"2458516018","title":"Ionis Pharmaceuticals, Inc.2024财年第二财季实现净利润-66.27百万美元,同比增加22.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458516018","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458516018?lang=zh_cn&edition=full","pubTime":"2024-08-10 00:17","pubTimestamp":1723220250,"startTime":"0","endTime":"0","summary":"8月10日,Ionis Pharmaceuticals, Inc.公布财报,公告显示公司2024财年第二财季净利润为-66.27百万美元,同比增加22.30%;其中营业收入为2.25亿美元,同比增加19.68%,每股基本收益为-0.45美元。机构评级:截至2024年8月10日,当前有22家机构对Ionis Pharmaceuticals, Inc.目标价做出预测,其中目标均价为61.77美元,其中最低目标价为37.00美元,最高目标价为82.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408100017419f1e1054&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408100017419f1e1054&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS"],"gpt_icon":0},{"id":"2457776290","title":"Ionis Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.05%报46.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457776290","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457776290?lang=zh_cn&edition=full","pubTime":"2024-08-05 22:11","pubTimestamp":1722867091,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日22时11分,Ionis Pharmaceuticals, Inc.股票出现波动,股价大幅跳水5.05%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为2.47%。Ionis Pharmaceuticals, Inc.公司简介:Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis广泛的临床和临床前产品链治疗多种疾病,重点是心血管、代谢、严重和罕见疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080522113196823fa7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080522113196823fa7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2456023715","title":"高盛:维持Ionis Pharmaceuticals(IONS.US)评级,由卖出调整至卖出评级, 目标价由33.00美元调整至37.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456023715","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456023715?lang=zh_cn&edition=full","pubTime":"2024-08-03 00:37","pubTimestamp":1722616623,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1668664300.SGD","IE00BFXG1179.USD","LU2237443549.SGD","LU1791807156.HKD","BK4585","LU2237438978.USD","BK4533","LU2237443382.USD","BK4139","LU2237443978.SGD","BK4127","LU2237443622.USD","IE00BSNM7G36.USD","IE0002270589.USD","BK4550","LU0106831901.USD","IE00B19Z3581.USD","BK4552","IE00B19Z3B42.SGD","IONS","IE0034235188.USD","BK4588","BK4504"],"gpt_icon":0},{"id":"2456827512","title":"Ionis Pharmaceuticals, Inc.盘中异动 早盘大幅下跌5.03%报48.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456827512","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456827512?lang=zh_cn&edition=full","pubTime":"2024-08-02 21:47","pubTimestamp":1722606442,"startTime":"0","endTime":"0","summary":"北京时间2024年08月02日21时47分,Ionis Pharmaceuticals, Inc.股票出现波动,股价急速跳水5.03%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.86%。其相关个股中,Exicure, Inc.、Os Therapies Incorporated、Dermata Therapeutics, Inc.涨幅较大,Dermata Therapeutics, Inc.、Exicure, Inc.、Cns Pharmaceuticals, Inc.较为活跃,换手率分别为1196.71%、495.87%、39.13%,振幅较大的相关个股有Os Therapies Incorporated、Exicure, Inc.、Dermata Therapeutics, Inc.,振幅分别为54.19%、45.46%、37.50%。Ionis Pharmaceuticals, Inc.公司简介:Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080221472298e34b88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080221472298e34b88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2456471220","title":"加拿大蒙特利尔银行:下调Ionis Pharmaceuticals(IONS.US)评级,由优于大市调整至大市一致评级, 目标价由67.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456471220","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456471220?lang=zh_cn&edition=full","pubTime":"2024-08-02 17:15","pubTimestamp":1722590133,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IONS","BK4139","BK4207","BMO"],"gpt_icon":0},{"id":"2456439363","title":"Ionis Pharmaceuticals Inc 报告截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2456439363","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456439363?lang=zh_cn&edition=full","pubTime":"2024-08-01 22:24","pubTimestamp":1722522268,"startTime":"0","endTime":"0","summary":" * Ionis Pharmaceuticals Inc 公布了截至 6 月份的季度调整后每股亏损 45 美分,高于去年同期的每股-60 美分。* 营收同比下降 61.7%,至 7200 万美元;分析师预期为 1.5007 亿美元。* Ionis Pharmaceuticals Inc公布的本季度每股收益为亏损45美分。* 该公司报告的季度亏损额为 6600 万美元。* Ionis Pharmaceuticals Inc 的股价本季度上涨了 3.8%,今年迄今为止下跌了 2.2%。华尔街对 Ionis Pharmaceuticals Inc 的 12 个月目标价中位数为 61.00 美元。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2455967919","title":"Ionis Pharmaceuticals Inc 预计每股亏损 92 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455967919","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455967919?lang=zh_cn&edition=full","pubTime":"2024-07-31 03:31","pubTimestamp":1722367875,"startTime":"0","endTime":"0","summary":" * 艾奥尼斯制药公司 预计将在8月1日公布截至0001年1月1日的季度收入报告。* LSEG 分析师对 Ionis Pharmaceuticals Inc 的平均预期是每股亏损 92 美分。* 华尔街对 Ionis Pharmaceuticals Inc 的 12 个月目标价中位数为 61.00 美元,高于上一交易日的收盘价 50.24 美元。7月30日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"gpt_icon":0},{"id":"2454838006","title":"BUZZ--美国股票走势-FTAI Aviation、Check Point、Sage Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2454838006","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454838006?lang=zh_cn&edition=full","pubTime":"2024-07-25 01:00","pubTimestamp":1721840446,"startTime":"0","endTime":"0","summary":" * 个股异动的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 7月24日 - 华尔街周三下跌,科技股重镇纳斯达克指数领跌,此前特斯拉和 Alphabet 的季度业绩乏善可陈,引发了人们对大科技和人工智能引领的 2024 年股市涨势能否持续的质疑。美东时间12:05,道琼斯工业平均指数 下跌0.78%,报40,043.52点。标普500指数 下跌1.73%,报5459.64点;纳斯达克综合指数 下跌2.85%,报17484.604点。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["T","CHKP","LU","TXN","V","TMO","DDM","SGMO","PSQ","EL","KARO","DXD","LUMN","OTIS","BSX","IONS","QID","TSLA","FLEX","UDOW","BXMT","SFL","DOG","GEV","LU0820561818.USD",".DJI","ROP","QLD","SDOW","SQQQ","THC","DJX","GERN","LU1791710582.SGD","TQQQ","MNQmain","VSTM","ENPH","NQmain","SAGE",".SPX","EQT",".IXIC","FTAI","LU1791710400.SGD","IE00BFTCPJ56.SGD","RIVN","LW"],"gpt_icon":1},{"id":"2453552005","title":"BUZZ-利瑞克合伙公司(Leerink Partners)评级提升 Ionis 制药公司股价","url":"https://stock-news.laohu8.com/highlight/detail?id=2453552005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453552005?lang=zh_cn&edition=full","pubTime":"2024-07-24 19:46","pubTimestamp":1721821613,"startTime":"0","endTime":"0","summary":" 7月24日 - ** Ionis Pharmaceuticals 股价在盘前交易中上涨 1.2% 至 51.07 美元** Leerink Partners将该公司的评级从 \"市场表现 \"上调至 \"跑赢大盘\",并将预测价格从53美元上调至62美元。** 17家券商将该股评级为 \"买入 \"或更高,7家为 \"持有\",1家为 \"卖出\";他们的中位预测价格为61美元 - LSEG** 截至上次收盘,该股今年以来略有下跌","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","IONS"],"gpt_icon":0},{"id":"2453106864","title":"TD Cowen:维持Ionis Pharmaceuticals(IONS.US)评级,由买入调整至买入评级, 目标价由54.","url":"https://stock-news.laohu8.com/highlight/detail?id=2453106864","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453106864?lang=zh_cn&edition=full","pubTime":"2024-07-24 01:03","pubTimestamp":1721754203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4566","BK4207","BK4585","BK4139","IONS","TD"],"gpt_icon":0},{"id":"2453706014","title":"美国研究综述-高露洁-棕榄公司、麦凯森公司、微软公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2453706014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453706014?lang=zh_cn&edition=full","pubTime":"2024-07-23 15:21","pubTimestamp":1721719282,"startTime":"0","endTime":"0","summary":" 路透7月23日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括高露洁棕榄、麦凯森和微软。要点 * 高露洁棕榄公司 :TD Cowen给予买入评级;目标价110美元 * DR Horton Inc :摩根大通将目标价从163美元上调至180美元 * IQVIA Holdings Inc :贝尔德将目标价从235美元上调至251美元 * McKesson Corp :杰富瑞将目标价从620美元上调至670美元 * 微软 :Piper Sandler将目标价从465美元上调至485美元 以下是路透周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CL","SG9999002224.SGD","ZS","CELH","IE00BLSP4452.SGD","LU2237438978.USD","WPC","TRV","MP","WAL","META","FITB","IQV","MNST","BOH","CATY","IPAR","KMB","SGXZ81514606.USD","BFH","BSRR","CLX","IE0005OL40V9.USD","MCK","WELL","IE00BK4W5L77.USD","HBT","BKU","DX","CHD","VTR","INDV","BK4023","PG","LU2242646821.SGD","DHI","SGXZ99366536.SGD","CUBE","MSFT","TEX","SG9999002232.USD","VERX","TER","RGP","TFC","IONS","VZ","EXR","AZZ","SPFI"],"gpt_icon":0},{"id":"2453713989","title":"BUZZ-Ionis制药公司因神经紊乱药物研究数据而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2453713989","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453713989?lang=zh_cn&edition=full","pubTime":"2024-07-23 01:02","pubTimestamp":1721667756,"startTime":"0","endTime":"0","summary":" 7月22日 - ** Ionis Pharmaceuticals 股价上涨5.7%至50.53美元 ** 该公司称其治疗复杂遗传性疾病的实验性药物有助于 ,在一项早中期研究中改善了沟通、认知和运动功能。** 在百健 于5月份退出 ,IONS重新获得了ION582的独家经营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","IE00B19Z9Z06.USD","IONS","BUZZ","IE00B19Z9P08.USD","BK4139","BK4532","BIIB","BK4533","IE00B894F039.SGD","LU0109394709.USD","LU0320765992.SGD","LU0234570918.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2453930177","title":"Ionis Pharmaceuticals, Inc.盘中异动 股价大涨5.33%报50.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453930177","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453930177?lang=zh_cn&edition=full","pubTime":"2024-07-22 21:41","pubTimestamp":1721655700,"startTime":"0","endTime":"0","summary":"北京时间2024年07月22日21时41分,Ionis Pharmaceuticals, Inc.股票出现异动,股价快速拉升5.33%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.67%。其相关个股中,Mei Pharma, Inc.、Apollomics Inc C/Wts 01/04/2028 、木薯科学涨幅较大,Hepion Pharmaceuticals, Inc.、Scisparc Ltd.、60 Degrees Pharmaceuticals, Inc.较为活跃,换手率分别为99.69%、79.77%、20.11%,振幅较大的相关个股有Exicure, Inc.、Mei Pharma, Inc.、Hepion Pharmaceuticals, Inc.,振幅分别为17.19%、16.78%、15.41%。Ionis Pharmaceuticals, Inc.公司简介:Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722214140941f92c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722214140941f92c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2452945866","title":"B of A Securities:维持Ionis Pharmaceuticals(IONS.US)评级,由买入调整至买入评级, 目标价由64.","url":"https://stock-news.laohu8.com/highlight/detail?id=2452945866","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452945866?lang=zh_cn&edition=full","pubTime":"2024-07-17 01:41","pubTimestamp":1721151664,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2451913328","title":"Ionis Pharmaceuticals, Inc.盘中异动 股价大涨5.07%报49.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451913328","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451913328?lang=zh_cn&edition=full","pubTime":"2024-07-16 21:58","pubTimestamp":1721138320,"startTime":"0","endTime":"0","summary":"北京时间2024年07月16日21时58分,Ionis Pharmaceuticals, Inc.股票出现波动,股价快速上涨5.07%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.68%。Ionis Pharmaceuticals, Inc.公司简介:Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis广泛的临床和临床前产品链治疗多种疾病,重点是心血管、代谢、严重和罕见疾病。消息层面,截至21时58分,《美银证券维持Ionis Pharmaceuticals买入评级,上调目标价至67美元》资讯为影响Ionis Pharmaceuticals, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240716215840af9299f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240716215840af9299f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2446823567","title":"Ionis Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.01%报46.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446823567","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446823567?lang=zh_cn&edition=full","pubTime":"2024-06-25 23:28","pubTimestamp":1719329326,"startTime":"0","endTime":"0","summary":"北京时间2024年06月25日23时28分,Ionis Pharmaceuticals, Inc.股票出现异动,股价急速上涨5.01%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.75%。Ionis Pharmaceuticals, Inc.公司简介:Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis广泛的临床和临床前产品链治疗多种疾病,重点是心血管、代谢、严重和罕见疾病。消息层面,截至23时28分,《美银证券维持Ionis Pharmaceuticals买入评级,上调目标价至64美元》资讯为影响Ionis Pharmaceuticals, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240625232847941f0f73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240625232847941f0f73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2446860353","title":"美国研究综述-Alimera Sciences、Comtech Telecommunications、礼来公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2446860353","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446860353?lang=zh_cn&edition=full","pubTime":"2024-06-25 15:19","pubTimestamp":1719299996,"startTime":"0","endTime":"0","summary":" 路透6月25日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括 Alimera Sciences、Comtech Telecommunications 和礼来公司。要闻 * Alimera Sciences Inc :Craig-Hallum将其评级从 \"买入 \"下调至 \"持有\"。* Comtech Telecommunications Corp :杰富瑞将其评级从 \"表现不佳 \"上调至 \"持有\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLM","ZETA","BK4159","EAT","SUM","ALIM","WOLF","EPD","LU1861215975.USD","BK4023","VMC","LU0708995401.HKD","IONS","BK4144","BK4139","LU0061475181.USD","BK4011","LU0029874061.USD","XAIR","IE00BJT1NW94.SGD","LU0471298777.SGD","SNCY","LU1852331112.SGD","LU0128526141.USD","ALNY","FRPT","LU1861220033.SGD","LU0238689110.USD","LU0289739699.SGD","LU2237438978.USD","LU0456855351.SGD","POOL","LU2468319806.SGD","LU0266013472.USD","OMI","BK4590","LU0053671581.USD","IE00B1BXHZ80.USD","LU1150488135.SGD","OLLI","BK4520","CTVA","BK4539","AVAV","EXP","CMTL","FMC","RXO","LU1057294990.SGD","LLY"],"gpt_icon":0},{"id":"2446888136","title":"Ionis Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.19%报44.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446888136","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446888136?lang=zh_cn&edition=full","pubTime":"2024-06-25 02:16","pubTimestamp":1719253009,"startTime":"0","endTime":"0","summary":"北京时间2024年06月25日02时16分,Ionis Pharmaceuticals, Inc.股票出现波动,股价快速拉升5.19%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.83%。Ionis Pharmaceuticals, Inc.公司简介:Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis广泛的临床和临床前产品链治疗多种疾病,重点是心血管、代谢、严重和罕见疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240625021650aef65708&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240625021650aef65708&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2446007110","title":"BUZZ-Alnylam 因心脏病药物在关键研究中获得成功而跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2446007110","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446007110?lang=zh_cn&edition=full","pubTime":"2024-06-25 01:42","pubTimestamp":1719250931,"startTime":"0","endTime":"0","summary":" (更新) 6月24日 - ** Alnylam Pharmaceuticals 股价大涨40%至231.64美元,创下自2023年2月以来的最高水平 。** 如果涨势保持,市值将增加80多亿美元** 该公司称其心脏病药物vutrisiran在一项受到密切关注的后期研究中达到了 主要目标和所有次要目标** 该药物vutrisiran有助于将一种被称为ATTR-CM的罕见心脏病患者的死亡人数和心脏相关住院治疗人数减少33%。** ALNY 公司的药物通过关闭转甲状腺素蛋白的不规则生产而发挥作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BUZZ","BK4588","IONS","BK4505","ALNY","BK4535","BK4556","BBIO","LU1861559042.SGD","BK4548","LU1861558580.USD","NTLA","BK4585"],"gpt_icon":0},{"id":"2443644068","title":"伯恩斯坦研究公司:上调Ionis Pharmaceuticals(IONS.US)评级,由低于大市调整至大市一致评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2443644068","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443644068?lang=zh_cn&edition=full","pubTime":"2024-06-14 17:55","pubTimestamp":1718358925,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IONS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionispharma.com","stockEarnings":[{"period":"1week","weight":-0.0178},{"period":"1month","weight":-0.0637},{"period":"3month","weight":0.2507},{"period":"6month","weight":0.0503},{"period":"1year","weight":0.1799},{"period":"ytd","weight":-0.0776}],"compareEarnings":[{"period":"1week","weight":0.0423},{"period":"1month","weight":-0.0209},{"period":"3month","weight":0.0446},{"period":"6month","weight":0.1072},{"period":"1year","weight":0.258},{"period":"ytd","weight":0.1636}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司在反义药物发明和开发上处于行业领先地位,利用新药研发平台,公司研发了大量的一流药品。反义技术在基因学和药物之间打开了一条通道。凭着公司高效多产的药物研发平台,公司可以用反义药物拓展自身及其合作伙伴的药物种类,满足大量的药物需求。公司的策略是做公司最擅长的事--寻找独特的反义药物并开发这些药物,使其成为关键的临床值转折点。公司发明并进行新药早期研究,然后将药物授权给合作伙伴。公司通过把药物交给领先的制药公司进行后期开发来实现药物的最大价值,如Biogen Idec公司、百时美施贵宝公司、 健赞公司、赛诺菲公司、葛兰素史克公司和礼来制药公司。 该公司的旗舰产品 KYNAMRO,正朝着市场上家族性高胆固醇血症患者迈进。 该公司于1989年在美国加州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.019969},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.021252},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.021038},{"month":4,"riseRate":0.333333,"avgChangeRate":0.018116},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.065195},{"month":6,"riseRate":0.777778,"avgChangeRate":0.046176},{"month":7,"riseRate":0.777778,"avgChangeRate":0.0362},{"month":8,"riseRate":0.555556,"avgChangeRate":0.012194},{"month":9,"riseRate":0.5,"avgChangeRate":0.017352},{"month":10,"riseRate":0.125,"avgChangeRate":-0.044855},{"month":11,"riseRate":0.625,"avgChangeRate":0.116043},{"month":12,"riseRate":0.5,"avgChangeRate":0.010906}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}